| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
sigma (σ) receptor[1] dopamine transporter[1]
Rimcazole targets sigma receptors as an antagonist, with IC50 values of 1480 nM at sigma-1 and 386 nM at sigma-2 receptors. It also binds to the dopamine transporter (DAT) with an IC50 of 57.6 nM and inhibits dopamine uptake. The compound's sigma receptor antagonism and dopamine transporter inhibition contribute to its pharmacological profile. It was investigated as a potential antipsychotic agent and has been shown to reduce the stimulatory effects of cocaine in vivo. Rimcazole also binds to opioid receptor sigma 1 (OPRS1). |
|---|---|
| ln Vitro |
HCT-116p53+/+ cell counts are lowered concentration-dependently by rimcazole (1–50 μM; 24-48 hours) [2]. In cancer cells (HCT-116p53+/+ and MDA-MB-231 cells), rimcazole (50 μM; 1–24 hours) causes a transitory increase of HIF-1α protein, but not in normal human dermal fibroblasts [2].
In vitro studies demonstrate that Rimcazole is an antagonist at sigma receptors with IC50 values of 1480 nM at sigma-1 and 386 nM at sigma-2 receptors. It binds to the dopamine transporter with an IC50 of 57.6 nM and inhibits dopamine uptake. The compound is a carbazole analogue that acts partially as a sigma receptor antagonist. It has been shown to be a specific, competitive antagonist of sigma sites in brain. Rimcazole also binds to opioid receptor sigma 1. Its ability to interact with multiple targets makes it a useful research tool. |
| ln Vivo |
In vivo studies show that Rimcazole reduces the stimulatory effects of cocaine in vivo. It was capable of blocking sigma sites in vivo with an ID50 of 6 mg/kg i.p. in mice, as judged by an in vivo sigma receptor binding assay. The compound was evaluated in open-clinical trials and appeared to be effective in acute schizophrenic patients. However, it was not developed further as an antipsychotic. The compound's ability to modulate sigma receptors and dopamine transporters in vivo supports its use in neuroscience research.
|
| Enzyme Assay |
For sigma receptor binding assays, rat brain membrane preparations or cells expressing recombinant sigma receptors are incubated with radiolabeled ligands (e.g., [3H]-DTG or [3H]-haloperidol) and varying concentrations of Rimcazole. Non-specific binding is determined using excess unlabeled reference compound. Following incubation at 25°C for 60-120 minutes, bound and free radioligands are separated by rapid filtration through glass fiber filters. Filters are washed, dried, and radioactivity counted. IC50 values are calculated from competition curves. For dopamine transporter binding assays, similar protocols are used with [3H]-WIN35,428 or [3H]-GBR12935. Assays are performed in triplicate with appropriate controls.
|
| Cell Assay |
Western Blot Analysis[2]
Cell Types: HCT-116p53+/+ cells Tested Concentrations: 50 μM Incubation Duration: 1, 2, 3, 5, 6, 24 hrs (hours) Experimental Results: Accumulation of HIF-1α protein, maximal at 6 h. No change in p53 protein levels. HIF-1α protein levels returned to normal steady-state levels within 24 h. For in vitro cellular assays, cells expressing sigma receptors or dopamine transporters are cultured in appropriate media under standard conditions (37°C, 5% CO2). Rimcazole is dissolved in DMSO and diluted in culture medium to desired concentrations. Cells are treated with compound for specified durations. Dopamine uptake is measured by adding radiolabeled [3H]-dopamine and quantifying intracellular radioactivity. Sigma receptor-mediated effects can be assessed by measuring downstream signaling or cell viability. For antipsychotic activity assessment, standard cell-based assays for dopamine and sigma receptor function may be used. Each concentration is tested in replicate wells with vehicle controls. |
| Animal Protocol |
For in vivo animal studies, Rimcazole is typically formulated in suitable vehicles and administered via intraperitoneal (i.p.) injection. In sigma receptor binding assays, mice are treated with Rimcazole at doses around 6 mg/kg i.p. and sigma site occupancy is assessed. In cocaine interaction studies, animals are treated with Rimcazole prior to cocaine administration and behavioral responses (e.g., locomotor activity, convulsive effects) are measured. For antipsychotic studies, standard behavioral models such as conditioned avoidance response or PCP-induced hyperactivity may be used. Blood and brain tissue samples may be collected for pharmacokinetic analysis. All procedures must follow institutional animal care and use committee guidelines.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Rimcazole are characteristic of a small-molecule receptor antagonist. The compound has a molecular weight of 394.39 (dihydrochloride salt), formula C21H27N3·2HCl, and CAS number 75859-03-9. Purity: ≥98% (HPLC). Storage: at +4°C. Solubility: water 3.94 mg/mL (10 mM). The compound is a carbazole derivative. Specific pharmacokinetic parameters such as half-life, clearance, and oral bioavailability are not extensively reported in publicly available sources. In vivo studies have used intraperitoneal administration at 6 mg/kg.
|
| Toxicity/Toxicokinetics |
According to available safety information, Rimcazole is intended for laboratory research use only. Standard laboratory safety precautions should be followed when handling this compound, including the use of appropriate personal protective equipment (gloves, lab coat, safety goggles). The compound should be handled in a well-ventilated area. Avoid dust formation and inhalation. In case of skin contact, wash with plenty of soap and water. In case of eye contact, rinse cautiously with water for several minutes. No clinical toxicity data are available as the compound was not commercially developed.
|
| References |
|
| Additional Infomation |
Rimcazole dihydrochloride (BW 234U) is a carbazole derivative and sigma receptor antagonist with IC50 values of 1480 nM (sigma-1) and 386 nM (sigma-2). It also binds to the dopamine transporter with an IC50 of 57.6 nM and inhibits dopamine uptake. The compound was studied as a potential antipsychotic and showed efficacy in open clinical trials for acute schizophrenia. It reduces the stimulatory effects of cocaine in vivo and blocks sigma sites in vivo with an ID50 of 6 mg/kg i.p.. It is for research use only with no regulatory approvals reported.
|
| Molecular Formula |
C21H29CL2N3
|
|---|---|
| Molecular Weight |
394.38
|
| Exact Mass |
393.174
|
| CAS # |
75859-03-9
|
| Related CAS # |
Rimcazole;75859-04-0
|
| PubChem CID |
53388
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
499.1ºC at 760 mmHg
|
| Flash Point |
255.7ºC
|
| LogP |
5.737
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
26
|
| Complexity |
380
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C[C@@H]1CN(C[C@@H](N1)C)CCCN2C3=CC=CC=C3C4=CC=CC=C42.Cl.Cl
|
| InChi Key |
ZWHRZGHGYMUSRM-VWDRLOGHSA-N
|
| InChi Code |
InChI=1S/C21H27N3.2ClH/c1-16-14-23(15-17(2)22-16)12-7-13-24-20-10-5-3-8-18(20)19-9-4-6-11-21(19)24;;/h3-6,8-11,16-17,22H,7,12-15H2,1-2H3;2*1H/t16-,17+;;
|
| Chemical Name |
9-[3-[(3R,5S)-3,5-dimethylpiperazin-1-yl]propyl]carbazole;dihydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 12.5 mg/mL (31.70 mM)
H2O: < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (3.17 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (3.17 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.25 mg/mL (3.17 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5356 mL | 12.6781 mL | 25.3563 mL | |
| 5 mM | 0.5071 mL | 2.5356 mL | 5.0713 mL | |
| 10 mM | 0.2536 mL | 1.2678 mL | 2.5356 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
